管腔B型乳腺癌的研究进展  

Research progress of Luminal B breast cancer

作　　者：亓秉超 薛妍[1] 

机构地区：[1]第四军医大学西京医院肿瘤科,西安710032

出　　处：《肿瘤研究与临床》2015年第12期857-861,共5页Cancer Research and Clinic

基　　金：国家自然科学基金（81372478）

摘　　要：管腔（Luminal）B型乳腺癌是乳腺癌的主要亚型之一。患者的无病生存率、总生存率比Luminal A型低。Luminal B型常需要化疗、内分泌治疗，对于Luminal B／Her-2^＋亚型还需要抗Her-2治疗，但预后仍然不佳。随着对Luminal B型乳腺癌研究的日益深入，新的治疗靶点不断出现，有望提高这型患者的治疗效果。文章就Luminal B型乳腺癌的临床病理特点、影响预后的因素、常规的治疗手段和新的治疗靶点作一综述。Luminal B breast cancer is a main subtype of breast cancer. Disease free survival and overall survival rate of patients with Luminal B subtype are lower than those of patients with Luminal A subtype. Luminal B breast cancer is often treated with chemotherapy and endocrine therapy, and anti-Her-2 therapy is also essential for Luminal B/Her-2 positive breast cancer, but the prognosis is still poor. With the increasing understanding of Luminal B breast cancer, new targets are developed and used for improving treatment effect.This review will describe the clinical and pathological features, factors affecting prognostic, common treatments and new therapeutic targets for Luminal B breast cancer.

关 键 词：乳腺肿瘤 LUMINAL B型 内分泌治疗 靶向治疗 

分 类 号：R737.9[医药卫生—肿瘤]